Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 11;12(12):3737.
doi: 10.3390/cancers12123737.

Cardiovascular Health during and after Cancer Therapy

Kathryn J Ruddy  1 , Shruti R Patel  2 , Alexandra S Higgins  1 , Saro H Armenian  3 , Joerg Herrmann  4
Affiliations
Review

Cardiovascular Health during and after Cancer Therapy

Kathryn J Ruddy et al. Cancers (Basel). .

Abstract

Certain cancer treatments have been linked to specific cardiovascular toxicities, including (but not limited to) cardiomyopathy, atrial fibrillation, arterial hypertension, and myocarditis. Radiation, anthracyclines, human epidermal growth factor receptor 2 (Her2)-directed therapies, fluoropyrimidines, platinums, tyrosine kinase inhibitors and proteasome inhibitors, immune checkpoint inhibitors, and chimeric antigen-presenting (CAR)-T cell therapy can all cause cardiovascular side effects. Management of cardiovascular dysfunction that occurs during cancer therapy often requires temporary or permanent cessation of the risk-potentiating anti-neoplastic drug as well as optimization of medical management from a cardiovascular standpoint. Stem cell or bone marrow transplant recipients face unique cardiovascular challenges, as do patients at extremes of age.

Keywords: anthracycline; cardio-oncology; congestive heart failure; myocarditis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
ABCDEs to promote Cardiovascular Health in Cancer Survivors.
Figure 2
Figure 2
Common contributors to cardiovascular disease after cancer at extremes of age.
See this image and copyright information in PMC

References

    1. Lenneman C.G., Sawyer D.B. Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment. Circ. Res. 2016;118:1008–1020. doi: 10.1161/CIRCRESAHA.115.303633. - DOI - PubMed
    1. Zamorano J.L., Lancellotti P., Rodriguez Munoz D., Aboyans V., Asteggiano R., Galderisi M., Habib G., Lenihan D.J., Lip G.Y.H., Lyon A.R., et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) Eur. Heart J. 2016;37:2768–2801. - PubMed
    1. Roychoudhuri R., Robinson D., Putcha V., Cuzick J., Darby S., Moller H. Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: A population-based study. BMC Cancer. 2007;7:9. doi: 10.1186/1471-2407-7-9. - DOI - PMC - PubMed
    1. Van Nimwegen F.A., Schaapveld M., Janus C.P., Krol A.D., Petersen E.J., Raemaekers J.M., Kok W.E., Aleman B.M., Van Leeuwen F.E. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175:1007–1017. doi: 10.1001/jamainternmed.2015.1180. - DOI - PubMed
    1. Stone C.R., Mickle A.T., Boyne D.J., Mohamed A., Rabi D.M., Brenner D.R., Friedenreich C.M. Treatment for lymphoma and late cardiovascular disease risk: A systematic review and meta-analysis. Health Sci. Rep. 2019;2:e135. doi: 10.1002/hsr2.135. - DOI - PMC - PubMed